{"id":483005,"date":"2026-06-04T16:54:08","date_gmt":"2026-06-04T16:54:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/483005\/"},"modified":"2026-06-04T16:54:08","modified_gmt":"2026-06-04T16:54:08","slug":"long-term-follow-up-of-three-first-line-regimens-in-mantle-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/483005\/","title":{"rendered":"Long-Term Follow-Up of Three First-Line Regimens in Mantle Cell Lymphoma"},"content":{"rendered":"


\n \t\t By Matthew Stenger<\/a>

\n\t\t

\n\t\t
\n\t\t Posted: 6\/4\/2026 10:04:00 AM
\n\t\t

\n Last Updated: 6\/4\/2026 11:07:23 AM
\n\t\t \n\t\t<\/p>\n

<\/p>\n

In an analysis reported in The Lancet<\/a>, Dreyling et al provided long-term findings with three first-line regimens in the phase III TRIANGLE trial among patients aged 18 to 65 years with mantle cell lymphoma.<\/p>\n

Study Details<\/p>\n

In the international (13 European countries and Israel) open-label trial, 870 patients with untreated stage II to IV disease suitable for autologous stem cell transplantation (ASCT) were randomly assigned 1:1:1 between July 2016 and December 2020 to:<\/p>\n

Control group A (n = 288), with treatment consisting of six alternating 21-day cycles of R-CHOP and R-DHAP or R-DHAOx, followed by ASCT
\nExperimental treatment A+I group (n = 292), with treatment consisting of the addition of ibrutinib on days 1 to 19 of R-CHOP cycles and as 2-year maintenance after ASCT
\nExperimental treatment I group (n = 290), with treatment consisting of the addition of ibrutinib with no ASCT.<\/p>\n

The initial results from the trial showed that adding ibrutinib to standard first-line immunochemotherapy improved failure-free survival.<\/p>\n

Key Findings<\/p>\n

Median follow-up was 54.9 months (95% confidence interval [CI] = 54.4\u201356.0 months).<\/p>\n

Group A+I did not show superiority over group I, with a 4-year failure-free survival of 82% (95% CI = 78%\u201387%) vs 81% (95% CI = 76%\u201386%; hazard ratio [HR] = 0.86, 98.33% CI = 0.00\u20131.27, P = .21). Group A+I was superior to group A (70%, 95% CI = 65%\u201376%; HR = 0.63, 98.33% CI = 0.00\u20130.89, P = .0026). Group A did not show superiority over group I (HR = 1.45, 98.33% CI = 0.00\u20132.02, P = .99).<\/p>\n

Overall survival at 4 years was 88% (95% CI = 84%\u201392%) in group A+I vs 81% (95% CI = 76%\u201385%) in group A (HR = 0.59, 95% CI = 0.38\u20130.92, P = .0036), and 90% (95% CI = 87%\u201394%) in group I (HR vs group A = 0.57, 95% CI = 0.36\u20130.90, P = .0019).<\/p>\n

During maintenance or follow-up, the most common grade 3 to 5 adverse events were hematologic disorders, occurring in 54% of group A+I vs 28% of group I and 23% of group A, and infections, occurring in 34%, 26%, and 15% of patients, respectively.<\/p>\n

The investigators concluded: \u201cAfter a prolonged follow-up of 55 months, both ibrutinib-containing groups showed relevant improvements not only in failure-free survival\u2014a modified form of progression-free survival\u2014but also in overall survival. In contrast, the addition of ASCT to an ibrutinib-containing regimen had no supplementary benefit but increased toxicity. Induction treatment with ibrutinib and R-CHOP plus R-DHAP (or R-DHAOx), followed by 2 years of maintenance treatment with ibrutinib, should be considered as a new standard of care for younger patients with mantle cell lymphoma.\u201d<\/p>\n

Martin Dreyling, MD, PhD, of the Department of Medicine III, LMU University Hospital, Munich, Germany, is the corresponding author for The Lancet article.<\/p>\n

DISCLOSURE: The study was funded by Janssen. For full disclosures of the study authors, visit thelancet.com<\/a>.<\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":" By Matthew Stenger Posted: 6\/4\/2026 10:04:00 AM Last Updated: 6\/4\/2026 11:07:23 AM …\n","protected":false},"author":2,"featured_media":483006,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[61,60,82],"class_list":["post-483005","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science","tag-ie","tag-ireland","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/483005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=483005"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/483005\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/483006"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=483005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=483005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=483005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}